OTCMKTS:IMMD - ImmuDyne Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 06/21/2018)
Today's Range
Now: $0.2150
50-Day Range N/A
52-Week Range
Now: $0.2150
Volume17,717 shs
Average Volume88,094 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Immudyne, Inc., an Internet based direct response marketing company, manufactures and sells personal care and nutritional supplement products. Its products portfolio include Shapiro MD, a shampoo, conditioner, and leave-in foamer for men and women; and iNR Wellness, a daily nutritional supplement that contains yeast, oat, and mushroom beta glucans. The company sells its products worldwide through technology infrastructure and relationships with agencies, third party marketers, and online advertising platforms, as well as through its Websites inrwellness.com and shapiromd.com. The company was formerly known as Anina Resources, Inc. Immudyne, Inc. was incorporated in 1987 and is based in New York, New York.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Current SymbolOTCMKTS:IMMD



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive IMMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMD and its competitors with MarketBeat's FREE daily newsletter.

ImmuDyne (OTCMKTS:IMMD) Frequently Asked Questions

What is ImmuDyne's stock symbol?

ImmuDyne trades on the OTCMKTS under the ticker symbol "IMMD."

Has ImmuDyne been receiving favorable news coverage?

Headlines about IMMD stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmuDyne earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for ImmuDyne.

Who are some of ImmuDyne's key competitors?

What other stocks do shareholders of ImmuDyne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuDyne investors own include Marijuana Company Of America (MCOA), Vuzix (VUZI), Dicks Sporting Goods (DKS), Cara Therapeutics (CARA), Oracle (ORCL), Amarin (AMRN), BioTelemetry (BEAT), CoStar Group (CSGP), Healthequity (HQY) and Myriad Genetics (MYGN).

Who are ImmuDyne's key executives?

ImmuDyne's management team includes the folowing people:
  • Mr. Justin Schreiber, CEO, Pres & Director (Age 35)
  • Mr. Robert Kalkstein, Chief Financial Officer (Age 36)
  • Mr. Stefan Galluppi, COO, CTO & Chief Exec. Officer of Immudyne PR (Age 31)
  • Dr. Joseph V. DiTrolio M.D., Chief Medical Officer of North America & Director (Age 67)
  • Mr. Todd Goldman, Sr. VP of Marketing and Sales

What is ImmuDyne's stock price today?

One share of IMMD stock can currently be purchased for approximately $0.2150.

What is ImmuDyne's official website?

The official website for ImmuDyne is http://www.immudyne.com/.

How can I contact ImmuDyne?

ImmuDyne's mailing address is 1460 BROADWAY, NEW YORK NY, 10036. The company can be reached via phone at 866-351-5907.

MarketBeat Community Rating for ImmuDyne (OTCMKTS IMMD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about ImmuDyne and other stocks. Vote "Outperform" if you believe IMMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel